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Multiple myeloma (MM) is a malignant disorder charac-
terized by the accumulation of neoplastic plasma cells in
the bone marrow. Most patients suffer from osteolytic
lesions that cause pain and reduced quality of life, and
may result in hypercalcemia, fractures, and spinal root
or spinal cord compression. At diagnosis 80% of patients
already have pathological bone ﬁndings when evaluated
with conventional radiography (1).
MM causes increased bone resorption through osteo-
clast activation (2–6), and bone resorption is increased
even in patients without osteolytic lesions (7). In addi-
tion, MM also causes decreased bone formation (8–11).
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290 ª 2010 John Wiley & Sons A/SBone formation is primarily impaired in patients with
overt osteolysis, whereas no decrease in bone formation
is observed in MM without osteolysis or in monoclonal
gammopathy of undetermined signiﬁcance (MGUS)
(7, 12). Likewise, osteoblasts from patients with MM
with bone disease are more prone to apoptosis compared
to osteoblasts from patients with MM without bone dis-
ease (13). Thus, it appears that osteolysis becomes appar-
ent only when increased bone resorption is not
compensated for by the formation of new bone (i.e.
‘imbalanced remodeling’).
Bisphosphonates, which are the only registered drugs
for the treatment of osteolysis in MM (14), mainly target
the increased bone resorption caused by osteoclasts (15).
The very signiﬁcant inhibition of osteoclasts obtained by
treatment with potent bisphosphonates may in fact inhi-
bit bone formation as some osteoclast activity seems to
be important for the stimulation of osteoblasts (16).
Indeed, a 50% reduction of osteoblast activity has been
observed after initiation of bisphosphonate treatment
(17). Accordingly, the protection against osteolysis
offered by bisphosphonate treatment is only partial (18).
Furthermore, osteoblast function remains impaired when
MM has been brought into remission with standard che-
motherapy (19), and healing of established bone lesions
is rarely observed (20).
Evidence suggesting that bortezomib, the ﬁrst clinically
available proteasome inhibitor, could overcome the
osteoblast inhibition observed in MM was provided from
the APEX trial where serum alkaline phosphatase (AP)
was found to be increased in patients responding to bort-
ezomib treatment (21). It was clearly demonstrated that
the stimulatory effect on bone formation was induced by
bortezomib as no increase in AP was observed in
patients responding to the treatment arm lacking bort-
ezomib. Subsequent clinical studies conﬁrmed and
extended this observation, showing that the increase in
AP was caused by the bone-speciﬁc alkaline phosphatase
(bALP) (22–24). Cell culture studies on human as well as
murine osteoblast cell lines and animal studies have dem-
onstrated that bortezomib stimulates osteoblasts and
bone formation (25–30). Furthermore, Giuliani et al. (31)
demonstrated that bortezomib treatment increases the
number of osteoblasts in the bone marrow of patients
with MM. So far, however, the clinical studies have been
performed in patients with relapsing MM who have
received prior chemotherapy, treatment with bisphospho-
nates, and frequently have also been treated with gluco-
corticoids, which are known to inhibit bone formation
(32, 33).
In this study, we report that bortezomib used alone
and in combination with a glucocorticoid as front-line
treatment in previously untreated, bisphosphonate-naı¨ve
patients stimulates bone formation not only as shown
by an increase in bALP but also through the use of a
novel bone marker, pro-collagen type I N-terminal pro-
peptide (PINP) that is released as collagen is deposited
and becomes insoluble during the formation of the
organic bone matrix (34) and may, therefore, be a better
marker for ongoing bone formation. We also found that
the formation of new bone, as reﬂected by an increase
in serum PINP, was inhibited by the addition of a glu-
cocorticoid to the treatment with bortezomib and
extended the observations by in vitro studies demonstrat-
ing that pulse-treatment with bortezomib induced
osteoblast differentiation which was inhibited by gluco-
corticoid treatment, while osteoblast proliferation was
not affected.
Material and methods
The study was conducted as a prospective bicenter non-
randomized phase II clinical trial in accordance with the
Helsinki declaration and ‘Good Clinical Practice’ guide-
lines, and was approved by the Danish Medicines
Agency, the Regional Ethical Committee, and the Dan-
ish Data Protection Agency. All patients gave informed
consent. The study received EudraCT number 2006-
002464-26 and trial registration number NCT00436059
at clinicaltrial.gov.
Only previously untreated newly diagnosed patients
with MM were included in the trial. Patients who had
previously received bisphosphonate treatment intrave-
nously or orally for any indication were excluded from
the study. A performance status of three or better and a
life expectancy of at least 3 months and measurable dis-
ease were required for inclusion. All patients received
four cycles of bortezomib 1.3 mg⁄m
2. Each cycle lasted
3 wk and bortezomib was administered by i.v. push on
day 1, 4, 8 and 11. The ﬁrst cycle was given as monother-
apy and in the three subsequent cycles bortezomib was
given in combination with dexamethasone 20 mg on the
day of bortezomib infusion and on the following day.
Patients
Twenty consecutive patients from Vejle Hospital or
Odense University Hospital were included in the trial
(ten males and ten females). The median age of the
patients was 68.5 yr (range: 51–85 yr), 15 patients had
IgG myeloma, three patients IgA myeloma and two
patients had light chain disease only. Response was mon-
itored at least every third week, prior to the initiation of
a new treatment cycle by measurements of serum
M-component (IgG or IgA), serum-free light kappa⁄
lambda chains (FLC), creatinine, ionized serum calcium
and other relevant laboratory parameters. Likewise, a
careful physical examination, evaluation of performance
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tion were conducted every 3 wk. Thrombocyte levels
were measured prior to each bortezomib infusion.
After four treatment cycles, treatment response was
evaluated according to the International Uniform
Response Criteria for Multiple Myeloma (35).
Markers of bone turnover
The bone turnover markers bALP, PINP, Dickkopf 1
(DKK-1) and N-terminal crosslinked telopeptide of type
I collagen (NTX-I) were measured together with parathy-
roid hormone (PTH), calcium and albumin during the
study period. Blood samples, used for the measurement
of bone turnover, were collected in the morning from
fasting patients. Urine samples were collected as fasting
second void morning urine. The samples were immedi-
ately centrifuged and stored at )80 C. Samples were col-
lected before the ﬁrst infusion of bortezomib on day 1
and subsequently on days: 2, 3, 4, 8, 9, 10, 11, 21, 24,
28, 31, 42, 52, 63 and 73 of the study period. All samples
from the individual patients were analyzed in the same
batch to minimize analytical variation. Serum bALP was
measured with a non-competitive enzyme immunoassay
technique (Quidel Corporation, San Diego, CA, USA).
Serum PINP was measured by a two-site immunoassay
detecting both mono and trimetric forms of intact PINP
(Roche Diagnostics, Hvidovre, Denmark). DKK-1, an
osteoblast inhibitor, was measured in plasma using an
enzyme-linked immunoassay (Biomedica, Wien, Austria).
To evaluate bone resorption, we measured urine NTX-I
(Ostex International, Seattle, WA, USA) by competitive
enzyme immunoassay techniques. bALP, PINP, DKK-1
and NTX-I were all analyzed in duplicates. PTH was
measured by an electrochemiluminescence technique that
measures intact PTH (Roche Diagnostics). Calcium and
albumin were measured by colorimetric methods (Roche
Diagnostics).
In vitro studies of osteoblasts
Human adipose-derived stem cells (ADSCs) (Invitrogen,
Taastrup, Denmark) capable of differentiating into
osteoblasts, and which serve as a model for pre-osteo-
blasts, were used to analyze the effects of bortezomib
and glucocorticoid administration on osteoblastic precur-
sor cells (undifferentiated ADSCs) and on more mature
osteoblasts (differentiated ADSCs) (36–38). The cells
were grown in a humidiﬁed incubator with 5% CO2 at
37 C. For experiments on osteoblastic precursors, the
cells were grown in MesenPro RS Medium (Invitrogen)
and cultured for a maximum of four passages. For
experiments on more mature osteoblasts the ADSCs
were taken into culture, grown for one passage and
reseeded at a density of 5000 cells⁄cm
2 in well plates.
The cells were then cultured for 24 h in MesenPro RS
Medium where after the medium was exchanged with
medium from the StemPro Osteogenesis Differentiation
kit (Invitrogen), and the cells were allowed to differenti-
ate for 10 d with medium renewal every 3–4 d.
To test the effects of bortezomib and glucocorticoid
treatment on undifferentiated or differentiated ADSCs,
the cells were exposed during in vitro culture conditions
to: (i) a 3-h pulse treatment with bortezomib 25 nm as
described previously (39) and then placed in control
medium, (ii) continuous exposure to 5 lm prednisolone
(corresponding to a daily oral dose of approximately
20 mg dexamethasone) for 48 h or (iii) control medium.
For all conditions, 0.5% DMSO (solvent of predniso-
lone) was added. The cells were harvested after 48 h for
response evaluation. We chose to use pulse-treatment
with bortezomib to better mimic the in vivo conditions
where the drug is given as a bolus infusion and the
serum level quickly reaches a peak after which it is rap-
idly taken up by the tissue and is subsequently followed
by a slow release and elimination (39, 40).
AP activity of cultured cells
Human ADSCs were washed after deﬁned periods in cul-
ture, lysed in reaction buffer (60 mm Na2CO3,4 0 m m
NaHCO3, 0.1% TritonX-100, 2 mm MgSO4,4 m m
4-nitrophenyl phosphate) and incubated in the dark for
30–60 min until a yellow color was visible. A sample of
the lysate was taken aside and used to determine the pro-
tein concentration according to the instructions by the
supplier of the kit (Bio-Rad Protein Assay; Bio-Rad,
Copenhagen, Denmark). The remaining solution was
mixed with 1 volume of 1 m NaOH and OD405 was
measured on a plate reader (Synergy HT; Bio-Tek,
Winooski, VT, USA) along with a standard curve of
4-nitrophenol. Results are given both as total AP activity
and as AP activity per lg of protein in the extract. The
measurements were done in ﬁve replicates.
Cell proliferation
Undifferentiated ADSCs were seeded in culture wells at
a density of 7.1 · 10
3 cells⁄cm
2 and incubated for 24 h.
Subsequently, cells were pulse-treated with bortezomib as
described, washed and cultured for 48 h or alternatively
exposed to prednisolone for 48 h. The cells were then
ﬁxed and stained with May-Gru ¨ nwald as previously
described (41). Cell proliferation was determined by
counting the surface in the culture well covered by cells
using a graticule with 100 points inserted into the ocular
using a 10· objective (Zeiss AxioVert; Carl Zeiss,
Birkerød, Denmark). Wells of a 96 well-plate were
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The percent cell surface area was determined as an aver-
age for the 19 squares in ﬁve replicates.
Analysis of gene expression
For gene expression analysis, ADSCs were seeded at a
density of 4.3 · 10
4 cells⁄cm
2 and incubated for 24 h using
either immature or differentiated osteoblasts derived as
described earlier. The cells were then either pulse-treated
with bortezomib or exposed to prednisolone for 24 h as
described. Medium was removed, the cell layer was
washed three times in PBS followed by lysis of the cells in
the plate and isolation of RNA according to the instruc-
tions by the supplier of the kit (Trizol Plus RNA Puriﬁca-
tion kit; Invitrogen). cDNA was generated using 500 ng
RNA and the iScript kit (Bio-Rad) according to the
instructions by the supplier. Subsequently, Q-PCR was
performed using the TaqMan approach according to
instructions by the supplier. The Q-PCR was run on a
Realtime PCR machine (7900HT; Applied Biosystems,
Foster City, CA, USA). As reference genes, Abl and GUS
were used. The expression levels of both genes were con-
verted into relative values by the use of an internal stan-
dard curve. Five replicates were done per sample. The
overall average expression levels of Abl and GUS were
used to normalize the expression levels of the genes of
interest. All TaqMan primer⁄probe sets were inventoried
and used according to the instructions by the supplier
(Applied Biosystems) (used primer⁄probes: GUS,
Hs99999908_m1; Abl, Hs00245443_m1; osteopontin,
Hs00959010_m1; collagen type I, Hs00164004_m1).
Statistical analysis
Changes in serum or urine levels of bALP, PINP, DKK-1,
NTX-I, PTH and calcium were analyzed by comparison
of the value of each marker at a given time point with
the same marker pre-treatment using a Wilcoxon signed
rank test. Spearman’s test was used to analyze for corre-
lation between calcium and PTH. Urine NTX-I was nor-
malized to urine creatinine and expressed as relative
values. Calcium levels were adjusted for variations of
serum albumin. Patients who left the protocol before
response evaluation was possible were analyzed as
responders. Cell culture experiments were analyzed using
an unpaired t-test. When analyzing Q-PCR levels, the
control values were normalized to one. All P-values are
two sided, and the signiﬁcance level was set at P £ 0.05.
Results
Twenty patients were included in the protocol. Fourteen
responded to treatment with a partial response or better,
and ten of these with a very good partial response or
better. Four patients responded with less than a partial
response. Two patients died before the ﬁnal response
evaluation could be conducted, one because of cerebral
hemorrhage the other because of gastro-intestinal bleed-
ing. These two patients were evaluated as responders.
Two patients underwent major orthopedic surgery pre-
ceding protocol inclusion causing abnormal high bone
formation markers (42). These two patients were
excluded from further analysis. Thus, fourteen patients
were evaluated as responders and four patients as non-
responders.
Markers of bone turnover in patients
Both bALP and PINP increased in patients responding
to bortezomib treatment (Fig. 1A,B). Their development
showed many similarities. Both markers reached a peak
value on day 42 after which the increase diminished.
The magnitude of changes was also strikingly similar
when analyzing values prior to each treatment cycle. At
the beginning of cycle two, bALP and PINP had
increased by 64.4% and 62%, respectively; at cycle three
by 98% and 101%; and at cycle four by 51% and 45%.
However, there were obvious dissimilarities when com-
paring bALP and PINP in responding patients. While
bALP showed no ﬂuctuation, a rapid and transient
decrease of 61% on average in PINP was observed dur-
ing cycle two to four. No decrease was seen in the ﬁrst
treatment cycle which was also the only cycle during
which bortezomib was given without the addition of
dexamethasone.
In patients who did not respond to treatment with a
partial response or better, no signiﬁcant changes in
bALP or PINP were observed (Fig. 1C,D).
Two patients received off-protocol treatment with glu-
cocorticoid prior to the planned time point. Patient A
received 100 mg prednisolone from day 12 to 53 because
of the risk of spinal cord compression. Patient B received
20 mg dexamethasone on day 11 and 12. Both patients
responded with an instant decrease in PINP, whereas
bALP remained unchanged (Fig. 2).
In responding patients, the osteoblast inhibitor
DKK-1 decreased rapidly after one treatment cycle and
reached a plateau at about 25% of the initial value
around day 30 (Fig. 3A). In patients not responding
to treatment, DKK-1 remained elevated (data not
shown).
The levels of the bone resorption marker NTX-I were
reduced by approximately 50% after one treatment
cycle in responding patients and remained relatively
constant thereafter (Fig. 3B). Patients with less than a
partial response showed a small but signiﬁcant decrease
in NTX-I (data not shown). PTH increased signiﬁcantly
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threefold of the baseline value at the beginning of cycle
two and then leveling off into a plateau around 2.5-fold
of the baseline level (Fig. 3C). The increase in PTH was
inversely correlated to decreasing calcium levels,
R = )0.465, P < 0.0001 (Fig. 3D). A similar but
statistically insigniﬁcant trend for both calcium and
PTH was found in non-responding patients (data not
shown).
Effect of bortezomib and glucocorticoid on osteoblast
precursors and differentiated osteoblasts in vitro
Human osteoblast precursors and differentiated osteo-
blasts were exposed to either bortezomib or prednisolone
as described in the Materials and Methods section.
Osteoblast precursors responded to the treatment with a
signiﬁcant increase in levels of AP activity (Fig. 4A), but
the difference became insigniﬁcant when AP levels were
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Figure 2 Effect on bone-speciﬁc alkaline phos-
phatase (bALP) and pro-collagen Type I N-termi-
nal peptide (PINP) of altering the time point of
administration of dexamethasone to two
patients. Two patients received treatment with
dexamethasone at day 12 and 11 respectively
in a violation of the protocol. In both cases,
bALP remained unchanged, whereas an imme-
diate decline in PINP was observed.
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Figure 1 Effect of treatment according to pro-
tocol on bone-speciﬁc alkaline phosphatase
(bALP) and pro-collagen Type I N-terminal pep-
tide (PINP) in responders and non-responders.
bALP increased twofold in responding patients
(A). PINP showed a similar increase (B). Both
values reached a maximum value at day 42.
Furthermore, PINP showed a transient signiﬁ-
cant decrease every time dexamethasone was
added. No signiﬁcant changes were observed in
non-responding patients (C–D). Response is
deﬁned as partial response or better. Results
are shown as mean values ± SEM from 14
(A–B) and 4 (C–D) patients. ***P < 0.001;
**P < 0.01; *P < 0.05 using a Wilcoxon signed
rank test.
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gesting that the increase in AP activity may reﬂect cell
proliferation (Fig. 4B). This assumption was supported
by the ﬁndings presented in Fig. 4C showing increased
cell growth with both treatments.
The impact of bortezomib or glucocorticoid on the
differentiation of osteoblast precursors was studied by
measuring an early osteoblast differentiation marker,
osteopontin, by Q-PCR (43). Treatment with bortezomib
resulted in a ﬁvefold increase in levels of osteopontin
while treatment with the glucocorticoid caused a strong
reduction of osteopontin (Fig. 4D). Thus, bortezomib
seems to induce both proliferation and differentiation of
osteoblast precursors, whereas the stimulation of osteo-
blast proliferation induced by glucocorticoides, from a
bone formation perspective, was counteracted by inhibi-
tion of differentiation.
When ADSCs were induced to differentiate into more
mature osteoblast-like cells before treatment with bort-
ezomib or glucocorticoid, AP levels were not signiﬁcantly
different from controls (Fig. 4E,F). However, in more
mature osteoblast-like cells, we found that treatment
with glucocorticoid induced a less mature phenotype as
shown by suppression of the differentiation marker colla-
gen type I (Fig. 4G). Thus, our in vitro ﬁndings show
that bortezomib and glucocorticoids may both induce
proliferation of osteoblasts, and that bortezomib may
also induce differentiation of osteoblast precursors while
glucocorticoids appear to inhibit the differentiation of
osteoblast precursors and induce an immature phenotype
in mature osteoblasts.
Overall, our in vitro ﬁndings seem consistent with the
interpretation that the increased serum bALP level in
patients could be because of enhanced growth and differ-
entiation of osteoblast precursors. The observed transient
decrease in PINP probably reﬂects reduced collagen type
I synthesis caused by treatment with the glucocorticoid.
Discussion
Osteolysis remains a major problem in MM and approxi-
mately 80% of patients have a pathological bone status
already at diagnosis. Impaired bone formation is a major
contributor to the development of clinically apparent
osteolysis. Over recent years, it has been shown that bort-
ezomib, the ﬁrst clinically approved proteasome inhibitor,
may increase the markers of bone formation, bALP and
osteocalcin, which are usually suppressed in MM. How-
ever, previously reported studies have been conducted on
a very heterogeneous population of patients with MM,
both with regard to earlier treatment regimens and with
regard to concurrent treatment with drugs known to have
an impact on bone remodeling, e.g. dexamethasone and
bisphosphonates. Here, we have studied for the ﬁrst time
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Figure 3 Effect of treatment on Dickkopf-1 (DKK1), N-terminal crosslinked telopeptide of type I collagen (NTX-I), parathyroid hormone (PTH), and
calcium in responders. DKK-1 showed a fourfold decline in responding patients (A). No changes were observed in non-responding patients (data
not shown). NTX-I declined twofold, however signiﬁcance is lost after the addition of dexamethasone (B). PTH increased signiﬁcantly from day 8
and onward (C). The changes in PTH were mirrored by a simultaneous decrease in calcium (D). The correlation coefﬁcient between calcium and
PTH is )0.465 P < 0.0001 (data not shown). Calcium levels were corrected to albumin levels. Response is deﬁned as partial response or better.
Results are shown as mean values ± SEM from 14 patients. ***P < 0.001; **P < 0.01; *P < 0.05; using a Wilcoxon signed rank test.
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when used as frontline treatment in bisphosphonate-naı¨ve
patients. We demonstrate that treatment with bortezomib
not only results in increased osteoblast activity but also
in an increase in actual bone matrix deposition evaluated
through the novel marker PINP (44). Owing to multiple
measuring points during the treatment period, we were
able to demonstrate a very early response after only 1 wk
of treatment, and after the ﬁrst treatment cycle both
bALP and PINP levels exceeded the upper normal range
of healthy adults.
The positive effect of bortezomib on bone formation
as demonstrated by biochemical markers reached a maxi-
mum after 6 wks, after which a slight decline was
QPCR Osteopontin
Control Bzb Gc
0
1
2
3
4
5
6
***
***
F
o
l
d
 
i
n
d
u
c
t
i
o
n
ALP 48 h index (µg protein)
Control Bzb Gc
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
µ
M
 
4
-
N
P
/
µ
g
 
p
r
o
t
e
i
n
D
G F E
C B A ALP 48 h
Control Bzb Gc
0
5
10
15
20
25 ***
**
µ
M
 
4
-
N
P
ALP Activity 48 h
Undiff Control Bzb Gc
0
5
10
15
20
25
30
35
40
45
50
55
60
65
µ
M
 
4
N
P
ALP 48 h index (µg protein)
Undiff Control Bzb Gc
0
1
2
3
4
5
6
µ
M
 
4
N
P
/
µ
g
 
p
r
o
t
e
i
n
Cell growth (cell surface)
Control Bzb Gc
0
10
20
30
40
50
60
70 ***
***
%
 
C
e
l
l
 
s
u
r
f
a
c
e
QPCR Collagen type I
Control Bzb Gc
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6 *
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
Osteoblast precursors 
Differentiated osteoblasts
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protein, B–C). Treatment with Bzb or Gc had a substantial effect on osteoblast proliferation almost doubling the area covered by cells after only
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from the APEX trial, where bortezomib was given as
single agent (21). One explanation for the biphasic devel-
opment of the curve could be that an initial direct osteo-
blast stimulation caused by bortezomib is later
counteracted by a decrease in total bone remodeling as
indicated by a decrease in the bone resorption marker
NTX-I. The decline observed in NTX-I was probably
caused partly by a reduced tumor burden, partly because
of a direct inhibitory effect of bortezomib on bone
resorption by osteoclasts (39, 45).
The delay of the addition of glucocorticoid treatment
in this study until cycle two made it possible to discrimi-
nate to some extent between the effect of bortezomib as
single agent vs. the effect of the combination of bortezo-
mib and dexamethasone. Unlike bALP which was rela-
tively unaffected by the addition of the glucocorticoid,
PINP showed a profound but transient decline each time
dexamethasone was given to the patient. As PINP better
reﬂects actual bone deposition than bALP, our ﬁnding
suggests that the beneﬁcial effect of bortezomib on bone
formation in vivo is partly inhibited by co-treatment with
a glucocorticoid. To elaborate further on this, we con-
ducted in vitro experiments on both osteoblast precursors
and more differentiated osteoblasts.
It has previously been shown in cell culture studies on
human as well as murine osteoblast cell lines and in animal
models that bortezomib may induce proliferation and dif-
ferentiation of osteoblast precursors and stimulate bone
formation (25–30). In our in vitro model of human osteo-
blast precursors, we found that not only bortezomib but
also glucocorticoid induced proliferation of osteoblast
precursors (46). However, unlike bortezomib, which stim-
ulated osteoblast differentiation, treatment with glucocor-
ticoid inhibited differentiation (47, 48). The inhibition of
osteoblast maturation by the glucocorticoid was found
both in osteoblast precursors (reduced osteopontin) and in
more mature osteoblasts (reduced collagen type I). The
expression of osteopontin by osteoblast precursors and col-
lagen type-1 by more mature osteoblasts was suppressed
by the glucocorticoid in both cases to levels that were
lower than the untreated control, suggesting that glucocor-
ticoids not only inhibit differentiation, but may actually
induce de-differentiation of osteoblast precursors and
osteoblasts. This is probably reﬂected in the clinical study
by a signiﬁcant drop in PINP levels, indicating the loss of
osteoblast maturity and capacity to form the organic bone
matrix by deposition of collagen type I. The persistently
elevated serum bALP in the clinical study could suggest
that bALP is clinically less relevant as a marker than
PINP, as bALP may just reﬂect proliferation of osteoblast
precursors with or without the capacity to form bone.
In the literature, the increased osteoblast activity seen
after bortezomib treatment has been ascribed to a decrease
in the osteoblast inhibitor DKK-1. We observed a rapid
decrease in DKK-1 after one treatment cycle in respond-
ing patients. However, it has been shown that DKK-1 also
declines in responding patients receiving non-bortezomib-
containing regimes (49). This result corresponds well with
DDK-1 over-expression being induced by the myeloma
cells (11). However, only bor-tezomib-containing regimens
have resulted in increased osteoblast activity. In our study,
there was no increase in bALP in patients without
response to treatment. Non-responders also had elevated
or stable DKK-1 levels. A possible explanation as to why
we observed no increase in bone formation markers in
non-responding patients, despite a direct positive effect of
bortezomib on osteoblasts precursors, could be that a con-
tinued high myeloma tumor burden resulted in high levels
of osteoblast inhibitors e.g. DKK-1 abrogating any such
effect. This hypothesis is in accordance with an observa-
tion showing that patients with lower levels of DKK-1
have greater increases of bALP (24).
In the paper by Zangari et al. (21), an increase in PTH
was noted along with an increase in bALP. In our study,
we observed a similar increase in PTH, which was tightly
correlated to, and may have been caused by a simulta-
neous decrease in calcium levels. Indeed, patients went
from having calcium levels in the upper normal range to
outright hypocalcaemia. Treatment with oral calcium
during this period could perhaps improve healing of
osteolytic bone lesions.
Here, we show that bortezomib when used in previ-
ously untreated and bisphosphonate-naı¨ve patients
increases both osteoblast activity and bone matrix depo-
sition. When using computer tomography, we could in
two cases demonstrate signs of actual healing only
3 months after initiation of therapy. The positive effect
of bortezomib is probably mediated through increased
proliferation and differentiation of osteoblast precursor
cells. However, we also show that the addition of a glu-
cocorticoid to bortezomib may inhibit the beneﬁcial
effect of bortezomib on bone formation. The inhibition
of osteoblasts by glucocorticoids was not detected by the
commonly used marker of bone formation, bALP.
Regarding MM treatment strategies, our results may sug-
gest that while at the time of diagnosis of MM the com-
bination of bortezomib and glucocorticoids with or
without the addition of other drugs is needed to obtain
rapid control of the disease, later in the course of the dis-
ease, when myeloma as such is well under control, sin-
gle-agent treatment with bortezomib may be justiﬁed in
order to improve healing of osteolytic lesions. A clinical
study in which patients with MM are randomized to
treatment with bortezomib or no treatment after high-
dose therapy and autologous stem cell transplantation
with a focus on bone healing has now been initiated
(EudraCT:2008-004264-39).
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